Appendix Table A3.
A Summary of the 14 Ongoing Repurposing Studies That Our Group Has Derived from Systematic Drug Repurposability Screening Analogous to That Presented in This Publication
| Therapeutic area | Precision repurposed indication | Drug status | Developmental stage |
|---|---|---|---|
| Gastroenterology | Recurrent Clostridium difficile colitis | Generic | Currently enrolling for phase II RCT |
| Ulcerative colitis | Reformulated generic | Preclinical/IND enabling | |
| Crohn's disease | Generic | RCT planned for 2019 | |
| Psychiatry/neurology | Chronic fatigue from elevated NE | Generic | Biomarker study currently enrolling |
| Anti-NMDAR-associated NPSLE/lupus fog | Generic (higher dose) | Currently enrolling for phase II RCT | |
| Oncology | Cancer metastasis | In development | Currently enrolling for pilot RCT |
| Neuropathy, pain, and inflammation | Trigeminal neuralgia | Reformulated generic | Enrolling for phase II RCT mid-2019 |
| Nerve-related headache pain | Reformulated generic | Preclinical/IND enabling | |
| Nephrology/hematology | Hemolytic uremic syndrome | Generic | Preclinical/IND enabling |
| Renal protection | Generic | Biomarker study planned for 2019 | |
| Skin, fibrotic and autoimmune disease | Wound healing in diabetic ulcer | Reformulated generic | Preclinical/IND enabling |
| Sjögren's syndrome | Generic | Enrolling for phase II RCT in late 2019 | |
| Sarcoidosis | Proprietary/generic | Preclinical | |
| Pediatrics | Pediatric osteomyelitis | Reformulated generic | Preclinical/IND enabling |
IND, Investigational New Drug; NE, norepinephrine; NMDAR, N-methyl-D-aspartate receptor; NPSLE, neuropsychiatric systemic lupus erythematosus; RCT, randomized controlled trial.